MOTS-c in Special Populations: Transplant, HIV, Aging, and Beyond
HealthRX.com
No human studies have given anyone MOTS-c
Key numbers
From the public record
MOTS-c in aging models: one mouse study and two cell studies
In D-galactose-treated mice, MOTS-c reduced abnormal fat deposits in liver, visceral fat and skin (Li 2019, animal study). In aged human placenta-derived stem cells in vitro, Yu 2021 reported a mitochondrial state closer to young cells. 3 studies are listed.
| Measure | Value | Note |
|---|---|---|
| Animal: Li 2019, animal model study, D-galactose-treated mice | Prevented abnormal fat accumulation | Exogenous MOTS-c reduced abnormal fat in D-galactose mice, possibly via mitochondrial dynamics. PMID 30967270 |
| Lab: Tsui 2026, laboratory and ex vivo study, HGL5 cells, mouse oocytes | Improved bioenergetics in aged cells | MOTS-c increased respiration in aged granulosa cells and partly improved aged mouse oocytes. PMID 42895211 |
| Lab: Yu 2021, in vitro study, aged human hPD-MSCs | Promoted homeostasis in aged cells | MOTS-c shifted aged human placenta-derived stem cells' mitochondrial state closer to young cells. PMID 33639272 |
How this was calculated
PubMed title and abstract search on 2026-11-13 for MOTS-c, MOTS c, MOTSc with transplant, kidney transplant, HIV, HIV-infected: 36 records, 9 abstracts read, 3 listed, each row summarising its own abstract.
MOTS-c peptide in transplant, HIV and aging populations: 0 human, 1 animal and 2 laboratory studies of 36 PubMed records.
See the public record for MOTS-c
At a glance
- Human studies of injected MOTS-c / none published [1]
- FDA status / not an approved drug, not a component of one [1]
- Human safety data / no MOTS-c reports in FDA's adverse-event database through March 9, 2025 [1]
- Approved dose / none; nominated products were 5 mg and 10 mg subcutaneous injections [1]
- Anti-doping status / prohibited at all times by WADA (S4.4.1) [5]
What is known for these groups
FDA searched PubMed, Embase, the Cochrane library and other sources and found no clinical study of MOTS-c given to humans; the 12 papers the nominator cited were not clinical studies [1]. FDA also found no animal toxicity studies and no pharmacokinetic data in humans or live animals; the only kinetic observation is rapid breakdown in human blood in the laboratory [1]. For a transplant recipient, a person with HIV or a frail older adult on several medicines, there is therefore no human exposure data to describe how MOTS-c behaves or what its risks are [1].
Where the treatment claims come from
Lee et al. reported MOTS-c in Cell Metabolism in 2015 as a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA gene. In mice it prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity, acting mainly on skeletal muscle through AMPK activation [1][2]. A late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median mouse lifespan from 912 to 970 days [1][3]. FDA says the molecular targets are unknown and no dose-response relationships were assessed [1].
The human studies did not give anyone MOTS-c
Reynolds et al. (Nature Communications, 2021) found that exercise raises endogenous MOTS-c expression in human skeletal muscle and in the circulation; participants were not given the peptide [3]. In a randomized trial of 30 healthy adults — 10 to endurance exercise, 10 to resistance exercise and 10 to control — humanin rose after endurance exercise while MOTS-c showed only a trend to increase, and plasma MOTS-c was not related to fitness [4]. A 2015 Aging Cell paper proposed that the m.1382A>C variant in the MOTS-c gene, specific to Northeast Asian populations, might help explain Japanese longevity — a hypothesis about a gene variant, not a trial of the peptide [6].
Status and dose
MOTS-c is not an FDA-approved drug [1]. It sits in the 'nominated but withdrawn' table of FDA's list of bulk substances that may raise significant safety risks. There FDA said it had identified no human exposure data by any route and that injectable peptides may pose an immunogenicity risk from aggregation and impurities; removal from category 2 was not a finding that MOTS-c is safe [7]. It appears in none of the categories on FDA's compounding bulk-substance lists for state-licensed pharmacies and physicians or for outsourcing facilities [8][9][10].
FDA staff proposed in July 2026 that MOTS-c not be added to the pharmacy bulks list. The Pharmacy Compounding Advisory Committee voted on 23 July 2026 in favor of adding it, against the staff recommendation; the vote is advice only and MOTS-c is not on the list [1][11]. HHS's October 2026 draft enforcement-discretion policy names MOTS-c acetate for subcutaneous or intramuscular injection and says HHS does not intend to take enforcement action against certain state-licensed pharmacies and physicians if its conditions are met. The notice says it is not binding, and it is not an approval [12][13]. WADA lists MOTS-c in S4.4.1 among AMPK activators, prohibited at all times in and out of competition [5][14].
There is no approved dose and no human dosing study of administered MOTS-c [1]. The nominated products were 5 mg and 10 mg subcutaneous injections; rodent doses of 0.5 to 15 mg/kg cannot be converted into human doses [1].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Can transplant patients take MOTS-c?
Does MOTS-c interact with HIV antiretrovirals?
Is MOTS-c allowed in sport?
References
Show all 14 referencesHide references
- U.S. Food and Drug Administration.
- Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
- Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
- von Walden F, Fernandez-Gonzalo R, Norrbom J, Emanuelsson EB, Figueiredo VC, Gidlund EK, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042.
- World Anti-Doping Agency.
- Fuku N, Pareja-Galeano H, Zempo H, Alis R, Arai Y, Lucia A, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity?. Aging Cell. 2015;14(6):921-3.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.
- World Anti-Doping Agency.